In the phase 3 POLARGO trial of 255 transplant-ineligible patients with relapsed or refractory DLBCL, Pola-R-GemOx vs R-GemOx lowered risk of death (HR 0.6; median OS 19.5 vs 12.5 months), but neuropathy (57% vs 29%) and fatal adverse events (12% vs 4%) were more common.
RCTn = 255
Matasar et al. Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial